Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
November 3, 2016 12:30 PM EDT
New results from the Phase III GALLIUM study which compared Gazyva®
(obinutuzumab) plus chemotherapy to Rituxan® (rituximab)
plus chemotherapy in previously untreated follicular lymphoma will be
presented in the Plenary Scientific Session
New results for Venclexta (venetoclax) and investigational medicine
emicizumab will also be presented at the meeting
FDA has accepted the Biologics License Application for a subcutaneous
formulation of Rituxan® (rituximab/hyaluronidase)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:... More
November 2, 2016 4:23 PM EDT
Net sales of $165.3 million, up 3.1%
Gross margin of 37.5%, up 30 basis points
Net income of $16.1 million, up 28.1%
Adjusted EBITDA of $34.1 million, 20.6% of net sales
ROGERS, Conn.--(BUSINESS WIRE)--
Rogers
Corporation (NYSE: ROG) today announced financial results for the
2016 third... More
November 2, 2016 1:00 AM EDT
15 oral presentations from 17 abstracts across six autoimmune
conditions
First presentation of Actemra data from GiACTA - the largest ever
clinical trial in people with giant cell arteritis (GCA), a condition
for which there has been no approved therapy in more than 50 years
New data from two studies investigating cardiovascular outcomes for
people with rheumatoid arthritis (RA) treated with Actemra
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),... More
